MOTS-c is a peptide encoded not by the nucleus but by mitochondrial DNA. The mouse metabolic data is strong and the human exercise association is real, but no large trial has tested injecting it into people.
Peptide Research
Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.
MOTS-c stands for mitochondrial open reading frame of the twelve S ribosomal RNA type-c. The name is unwieldy and the underlying fact is not: this is a peptide whose instructions sit inside mitochondrial DNA rather than in the cell nucleus, which is where essentially all of the human proteome is encoded.
Mitochondria carry their own small circular genome, a remnant of the ancient bacterial ancestry of the organelle. That genome was understood mainly as a set of instructions for components of the respiratory chain. The 2015 paper describing MOTS-c reframed part of it as a source of signalling molecules that leave the mitochondrion and act on the rest of the cell and on distant tissues.1
That reframing is why MOTS-c gets attention from serious researchers. It suggests mitochondria are not only the cell's power supply but also an endocrine tissue reporting their own state outward. If mitochondrial function declines with age, and mitochondria signal their state through peptides like MOTS-c, then those peptides become candidate messengers of metabolic aging rather than just markers of it.
The discovery is real and important. What it is not, on its own, is evidence that injecting the peptide helps a person. Those are separate claims that require separate experiments.
The original work reported that MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance, and it identified AMPK as the pathway involved.1 AMPK is the cell's energy-status sensor. It activates when cellular energy runs low and switches the cell from storing fuel to burning it, increasing glucose uptake and fat oxidation.
AMPK is also the pathway that metformin engages and the pathway exercise engages, which is exactly why the finding attracted attention. A peptide that activates the same sensor from a different direction is a legitimate metabolic drug candidate.
The specifics of the mouse results matter. Animals given MOTS-c were protected against diet-induced obesity and against the insulin resistance that normally accompanies it. That is a strong preclinical result: not a marginal shift in one biomarker but protection against the whole metabolic syndrome the diet was designed to produce.
It is also a mouse. Diet-induced obesity in a genetically uniform rodent on a defined high-fat chow is a controlled and unusually tractable model. Human metabolic disease develops over decades against a background of variable genetics, diet, sleep, medication, and activity. The rate at which metabolic interventions succeed in that model and then fail in people is high enough that the mouse result should be read as a reason to run a human trial rather than as a preview of its outcome.
The human evidence is real, and it is a different kind of evidence than people assume. MOTS-c has been characterised as an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis, with human measurements showing that exercise raises circulating MOTS-c alongside supporting work in animals.2
Read that carefully. Researchers measured MOTS-c in people, found levels rise with exercise, and found the peptide relates to muscle homeostasis and physical decline with age. Nobody in that work gave healthy humans injected MOTS-c and measured what happened to their metabolism over months.
The distinction between an association and an intervention is the entire question here. Exercise raises MOTS-c and exercise improves metabolic health. It does not follow that the MOTS-c is what produced the improvement, because exercise simultaneously changes hundreds of other things, from insulin sensitivity and mitochondrial density to blood pressure, lipid handling, and sleep quality. MOTS-c may be a mediator, a marker, or a bystander. The published human work does not distinguish between those possibilities.
Reviews of mitochondrial-derived peptides make the state of the field explicit: this is an emerging class with novel insights and therapeutic opportunities, framed as opportunity rather than as established therapy.3 Work on mitochondrial microproteins and mtDNA variants in athletic performance and age-related disease sits in the same category, describing associations and mechanisms rather than trial outcomes.4
There is a specific reason to be careful about assuming an injected version reproduces the endogenous one. MOTS-c produced inside a cell is released in response to a physiological trigger, in a particular pattern, in specific tissues, at concentrations the body regulates. An injection delivers a bolus into subcutaneous tissue on a schedule someone chose, with no feedback control.
Endocrinology is full of cases where that difference determines everything. The same molecule delivered continuously rather than in pulses can produce the opposite effect. Physiological signalling depends on pattern, not just presence, and no published human pharmacokinetic work establishes what an injected MOTS-c dose does to circulating levels or how long it persists.
Nobody has run the trial that would settle it. There is no large randomised study of injected MOTS-c for metabolic outcomes, weight, insulin sensitivity, physical performance, or anything else. Dosing protocols circulating in peptide communities are not derived from human dose-finding studies, because those studies have not been published. They are extrapolations from animal dosing scaled by bodyweight, which is a rough heuristic even when the underlying human trial exists, and this one does not.
MOTS-c is not an FDA-approved drug. It is also not currently legal to compound in the United States, meaning a licensed US compounding pharmacy cannot prepare it against a prescription.
The FDA's Pharmacy Compounding Advisory Committee reviewed several of these peptides in July 2026. PCAC is advisory and no rule has been issued. Statements that MOTS-c has been approved, banned, scheduled, or placed on a timeline describe something that has not been published.
What that leaves is research-chemical supply: vials labelled for research use only, sold by vendors who are not licensed pharmacies and are not inspected as such. Identity, purity, and sterility are seller assertions. For an injectable, non-sterile preparation carries infection risk that is immediate and unrelated to whether the peptide itself works.
MOTS-c claims tend to blur three separable things: the discovery, the mouse pharmacology, and the human association. Each is solid on its own terms. Stacked together and presented as a single body of support for injecting the peptide, they overstate what has been shown by a wide margin.
A cleaner reading: the discovery is a real advance in mitochondrial biology.1 The mouse metabolic protection is a strong preclinical result.1 The human data shows exercise raises endogenous levels and that the peptide tracks with muscle homeostasis and physical decline.2 The therapeutic case remains framed as opportunity in the review literature.34 No large human trial of the injected peptide exists.
There is an irony worth stating plainly. The single most reliable way to raise your MOTS-c that has actually been demonstrated in humans is exercise. That intervention is free, has an enormous evidence base for the exact metabolic outcomes MOTS-c is sold for, and does not require a vial from an unregulated vendor.
Exercise raises MOTS-c. That is the finding most often used to sell injections, and it is closer to an argument for exercise than an argument for injections.
Astra Editorial, reviewing the MOTS-c literature
No large human trials of injected MOTS-c have been published. Human research has measured endogenous MOTS-c levels, including the finding that exercise raises them, rather than testing the peptide as an administered drug.
It is encoded by mitochondrial DNA rather than the nuclear genome. That places it in a small class of mitochondrial-derived peptides that appear to signal mitochondrial status to the rest of the body.
No. MOTS-c is not FDA-approved and is not currently available for compounding in the United States. Product sold online comes from research-chemical suppliers operating outside pharmacy licensing and manufacturing oversight.
MOTS-c is not sold at Astra. It is not FDA-approved, and it is not currently available for compounding in the United States, so there is no legitimate prescription pathway to it today. The one MOTS-c-raising intervention demonstrated in humans is exercise. Keep reading in the Astra Learn library, and we will publish an update if a human trial or the regulatory picture changes.
This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.